header logo image


Page 723«..1020..722723724725..730740..»

Blind man’s sight restored after being hit by car – News24

February 8th, 2020 9:45 pm

A Polish man, who was blind for over two decades, isreportedly able to see again after he was hit by a car.

Local media said that Janusz Goraj from Gorzw Wielkopolskiin Poland was able to see properly two weeks after being involved in anaccident.

Janusz suffered from an allergic reaction that damaged theretina in his right eye. His left eye could only register shapes and light.

During an interview with Polsat News, Janusz said that hissight has been perfect after he was hit by a car while crossing the road in2018.

I fell on the car bonnet, hit my head and then I slippedand fell on the road, Janusz said.

Following the accident Janusz was taken to the IndependentPublic Provincial Hospital for hip surgery.

At a certain age such fractures dont heal so quickly, sohe had to be hospitalised, hospital spokesperson Agnieszka Wisniewska said.

At that time, doctors werent concerned about his visionbecause of his injuries.

Within two weeks his injuries had mostly mended with theadded bonus of his eyesight miraculously returning.

Janusz vision has been restored to such an extent that hedoesnt even need to wear his old glasses anymore.

Doctors were stunned by the incident, but they can now onlyspeculate as to what the reason behind his recovery is as Janusz declined totake part in further tests.

We dont quite know what caused it. Maybe it was the mixof drugs he was getting during that time, Wisniewska said.

One theory is that the large doses of anticoagulants (medicinethat helps prevent blood clots) mixed with his other medicine couldve helpedwith the patients unexpected eyesight return.

Incredibly Janusz is now able to live an independent lifeagain. He even got a job as a security guard at the same hospital where hissight came back.

We dont know if he specifically asked for the job or ifits just a coincidence, but he is working here with us, Wisniewska confirmed.

Source: Magazine Features

Read more here:
Blind man's sight restored after being hit by car - News24

Read More...

5 foods that will help you protect and improve your eyes – Pulse Nigeria

February 8th, 2020 9:45 pm

The first step to protecting your eyes is by paying attention to your diet. Those issues you're having with your eyes might be because of the nutrients that are missing in your diet. This article will show you the foods that would help you improve your eyesight.

It's no news that age, genetics and your electronic gadget has a way of affecting your eyesight. This is why you need to eat right especially if your eye defect is genetic. You don't have to worry about breaking the bank to keep up with this diet.

The foods can be found in the market. Below are the foods that would help protect and maintain your eyesight.

Fatty fish like salmon, sardines, and tuna contain nutrients that can help protect and maintain your eyesight. These fishes are rich in omega-3-fatty acid prevents macular degeneration, dry eyes, and cataracts. One of the ways you can enjoy this fish is by grilling it. You can avoid frying them so as not to reduce their nutritional value.

The benefits of consuming green leafy vegetables can never be overemphasized. Leafy green vegetables like spinach, kale, broccoli contain nutrients that delay the development of cataract and macular degeneration. These vegetables are also a great source of vitamin A which is healthy for the eyesight.

Britannica

For you to maintain your eyesight, you need some carotenoid in your body and carrot is the right food to get you that. It's loaded with beta-carotene which is antioxidant that's also a precursor for vitamin A, which strengthens the eyes. Your night vision will improve if you add carrots to your diet.

The Picture Pantry

The vitamins and nutrients present in egg protect the eyes against night blindness. The best way to get all the nutrients is by boiling it rather than frying.

ALSO READ: Stay healthy by having these nutritious foods for breakfast

This pepper is quite common in the market. Red bell pepper is a good source of vitamin A, C and other nutrients needed to maintain good eyesight. The nutrients keep your retina in good health as well as protecting your eyes from macular degeneration.

Read this article:
5 foods that will help you protect and improve your eyes - Pulse Nigeria

Read More...

Milton Keynes grandfather thanks the pioneer who saved his sight in medical first – Milton Keynes Citizen

February 8th, 2020 9:45 pm

The 80 year old was operated on by Sir Harold Ridley in 1956 when he was 16.

Jeffrey, a retired electrical engineer, said: Initially I was told by my local hospital that Id never be able to see with my right eye but my mum refused to accept that. We were eventually referred to Sir Harold Ridley at St Thomas Hospital. What he was doing wasnt widely known about then but he said he could help me.

By then the lens in my eye had gone opaque and my vision had started to get worse. Once my lens had been removed and the new one was inserted my vision was brilliant and it stayed that way for 30 years.

Jeffrey had accidentally pierced his right eye while playing darts. As a result he developed cataracts, a clouding of the lens in the eye which leads to a decrease in vision.

And as part of the 70th anniversary of the first successful lens implant operation - which was developed by Sir Harold, Jeffrey wanted to publicly thank the ophthalmologist, whose breakthrough has saved the sight of millions worldwide.

Sir Harold was a pioneer now so many people have the operation each day thanks to what he discovered.

He was a brilliant surgeon. I would have completely lost my vision in my right eye without him. It was great my mum pushed for treatment because my life could have been very different without vision in one eye."

It was only by 1986, that Jeffreys artificial lens had started to rub against his cornea so it was removed at St Thomas and he was given contact lenses and a corneal graft. He said: The team was amazed that the lens Sir Harold Ridley put in was still there. Ive done very well with my sight for so long."

Sir Harold made his medical breakthrough after treating a Spitfire pilot who had Perspex in his eye. He noticed that, unlike most foreign bodies, the eye did not reject Perspex. He used this discovery to create an artificial lens made of Perspex to replace those in eyes which became clouded by cataracts.

Previously people with cataracts had the cloudy lens of the eye surgically removed and then needed to wear powerful thick glasses. At the time Sir Harolds invention was a radical concept, which was initially resisted by much of the medical profession. By the 1980s it had become a routine procedure but involved a 1cm incision, stitches and a two-week recovery.

Today it is the most common eye operation in the world. It has evolved and now only requires an incision of just 2mm to insert a lens which unfolds within the eye, no stitches and a same-day discharge. Some patients may even have no need to wear glasses afterwards.

Excerpt from:
Milton Keynes grandfather thanks the pioneer who saved his sight in medical first - Milton Keynes Citizen

Read More...

The ‘eyes’ have it for Zenni Optical’s first Super Bowl spot – Campaign US

February 8th, 2020 9:45 pm

In what must be the most unusual media buy of Super Bowl LIV, Zenni, an online eyewear retailer, is airing spots only in Fox affiliate markets that have some tie-in to eyesight.

Zennis first Super Bowl commercial, featuring George Kittle, a tight end on the San Francisco 49ers, will appear in GlenVIEW, Ill., Mountain VIEW, Calif., ChEYEnne, Wyo., TallahasSEE, Fla, Jackson and Memphis TennesSEE and so forth.

"We wanted to get as creative as we could while finding the appropriate level of investment but with some level of scale," explained Sean Pate, Zennis brand communication officer. "We thought the vision centric markets made for a nice pun, while we primarily focus on the Bay Area and Chicago markets."

Pate estimated a media buy of less than $1 million.

Zenni, based in Novato, Calif., is the official eyewear of the San Francisco 49ers and the Chicago Bulls.

"While the 49ers are our hometown football team, we dont have any corporate connections to Chicago, however, both franchises are legacies of their sports and carry many millions of devoted fans not only in market, but across the country and internationally," said Pate. "As an e-commerce business with no retail in either location, the partnership with both teams gives us significance across the country."

The 30-second Kittle spot, created in conjunction with Beasley Media Group, Naples, Fla., and Scheme Engine, Los Angeles, features the stylish player in a range of Zenni eyewear. The spot shows him on the field, walking into the stadium and reviewing plays on an iPadSuper Bowl spot.

In a voiceover monologue, Kittle says: "Vision is critical to an athletes performance and protecting it is just as important as correcting it."

Zenni Optical, founded in 2003, is a pioneer in the online prescription eyewear niche, disrupting the category with eyewear averaging $40 a pair. Rashida Jones is another endorser who will appear in outdoor and print ads for Zenni through 2020.

"Youll see additional sports marketing investments and likely more celebrity engagement and other collaborations," said Pate. "We are in a major brand building and education mode right now."

More here:
The 'eyes' have it for Zenni Optical's first Super Bowl spot - Campaign US

Read More...

First in the U.S. Wireless Retinal Device for Advanced Age-related Macular… – ScienceBlog.com

February 8th, 2020 9:45 pm

UPMChas implanted the first patient in the United States with a new wireless retinal device as part of a clinical trial aimed atrestoring partial sightto patients with advanced age-related macular degeneration (AMD), a disease that leads to permanent blindness.

Vision research has advanced dramatically in the recent past and UPMC is at the forefront of this revolution. This is the first of many such breakthroughs led by UPMC and Pitt that will benefit patients with vision loss in our community and around the world, saidJos-Alain Sahel, director of theUPMC Eye Center, Eye and Ear Foundation chair of ophthalmology and distinguished professor at theUniversity of Pittsburgh School of Medicinewho initiated the trial at UPMC. We are proud to be the first center in the United States to test this next generation retinal implant that could help treat an incurable disease like AMD.

The system, called PRIMA, is designed to restore sight in patients blinded by retinal degeneration. It consists of a two-millimeter-by-two-millimeter, 30-micron thick miniaturized wireless photovoltaic chip, placed under the damaged retina and works in tandem with augmented reality glasses that have a built-in miniaturized camera and infrared projector.

The chip acts like a tiny artificial retina, made up of 378 tiny electrodes that convert infrared light from the glasses to electrical signals that are carried by the optic nerve to the brain. After receiving the implant, patients undergo an intensive rehabilitation program that trains their brains to understand and interpret the signals from the implant in combination with their remaining natural vision. Compared to earlier-generation implants, PRIMA is wireless and has significantly more electrodes, which allows for the transmission of more visual information.

This is an incredibly exciting first for us at UPMC and Im honored to be a part of it, saidJoseph Martel,the implanting surgeon at the UPMC Eye Center and the Pitt School of Medicine, and the principal investigator of the trial at UPMC. Im grateful to our patients who have volunteered to participate in this trial, without whom this would not be possible.AMD is the leading cause of vision loss in people older than 50. Today, it affects approximately 14 million people in the United States, and the prevalence is expected to rise as the baby boomers age. As AMD progresses, the center of vision becomes increasingly blurry. Atrophic AMD, which accounts for a large proportion of advanced cases, has no curative treatment available.

The UPMC feasibility trial is running in parallel with the first-in-human trial in France, which involves five patients with advanced AMD, who now have been followed for more than a year. The 12-month results from the French study demonstrated the ability of most patients to identify sequences of letters and there were nodevice-related serious adverse effects.

We are working with a great sense of urgency because the aging population of the United States, especially the western Pennsylvania region we live in, will see a significant rise in the number of patients at risk for vision loss through diseases like age-related macular degeneration, glaucoma and vascular eye disease, as well as earlier onset genetic conditions such as retinitis pigmentosa, said Sahel. This is why our physicians and researchers at UPMC and Pitt, in collaboration with our U.S. and international colleaguesespecially at the Paris Vision Institute at Sorbonne Universityare taking a multi-pronged effort to treat and rehabilitate patients with vision impairments.

In March 2019, UPMC broke ground on theUPMC Vision and Rehabilitation Tower at UPMC Mercy, which when completed, will provide advanced specialty clinical care and innovative programs for visually impaired patients. It also will be the home for the vision research program at Pitt and UPMC.

The PRIMA implant was invented by Daniel Palanker,professor of ophthalmology atStanford University, and licensed and developed byPixium Vision, a spin-off from the Paris Vision Institute. Sahel is a co-founder of Pixium and holds shares in the company.

More here:
First in the U.S. Wireless Retinal Device for Advanced Age-related Macular... - ScienceBlog.com

Read More...

Bone Marrow Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 – Jewish Life News

February 8th, 2020 3:49 am

The Global Bone Marrow Market study with 100+ market data Tables, Pie Chat, Graphs &Figures is now released by Data Bridge Market Research. The report presents awhole assessment of the Market covering future trend, current growth factors,attentive opinions, facts, and industry validated market data forecast till2026. Delivering the key insights concerning this industry, the report providesan in-depth analysis of the most recent trends, present and future businessscenario, market size and share of Major Players like Abbott; QIAGEN;Diazyme Laboratories, Inc.; Sanofi; CSL; STEMCELL Technologies Inc.; Lonza;HemaCare; PromoCell GmbH; Mesoblast Ltd; Lifeline Cell Technology, anInternational Stem Cell Company; Cellular Dynamics International, Inc.;ReachBio LLC; ATCC; Merck KGaA; Discovery Life Sciences; AllCells; ReeLabs Pvt.Ltd. and Gamida Cell.

Global bone marrow market is expected to register asubstantial CAGR of 6.05% in the forecast period of 2019-2026. The reportcontains data from the base year of 2018 and the historic year of 2017. Thisrise in market value can be attributed to the rising levels of success rateswith these procedures which are expected to result in higher adoption ratesalong with the rising levels of commercialization by the various researchcompanies regarding their products & services.

Avail 20% Discount on Buying This Report:Get aFree Sample Copy of the Report @ (Use Corporate email ID to Get HigherPriority) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-market&SR

Unlock new opportunities in Bone Marrow Market; the latestrelease from Data Bridge Market Research highlights the key market trendssignificant to the growth prospects, Let us know if any specific players orlist of players needs to consider gaining better insights.

The study given in this section offers detailsof key market players. It likewise clarifies the marketing strategies adoptedby these players as well as portrays their shareholdings in the global market.

How will the report help new companies toplan their investments in the market?

The market research report classifies the competitive spectrumof this industry in elaborate detail. The study claims that the competitivereach spans the companies

The report also mentions about the details such as the overallremuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongsidethe details of the company, such as company overview, buyer portfolio, productspecifications, etc., are provided in the study.

Market Drivers

Market Restraints

AndMore..Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-market&SR

Why Is DataTriangulationImportantIn Qualitative Research?

This involves data mining, analysis of theimpact of data variables on the market, and primary (industry expert)validation. Apart from this, other data models include Vendor Positioning Grid,Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid,Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysisand Vendor Share Analysis. Triangulation is one method used while reviewing,synthesizing and interpreting field data. Data triangulation has been advocatedas a methodological technique not only to enhance the validity of the researchfindings but also to achieve completeness and confirmation of data usingmultiple methods

Key Insights that Study isgoing to provide:

The 360-degree overview based on a global andregional level

Market Share & Sales Revenue by KeyPlayers & Emerging Regional Players

Competitors In this section, various industry leadingplayers are studied with respect to their company profile, product portfolio,capacity, price, cost, and revenue.

A separate chapter on Market Entropy to gaininsights on Leaders aggressiveness towards market [Merger & Acquisition /Recent Investment and Key Developments]

Patent Analysis** No of patents / Trademarkfiled in recent years.

A complete and useful guide for new marketaspirants

Forecast information will drive strategic,innovative and profitable business plans and SWOT analysis of players will pavethe way for growth opportunities, risk analysis, investment feasibility andrecommendations

This study will address some of the mostcritical questions which are listed below:

GetEnquiry About This Comprehensive Report @: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-market&SR

StrategicPoints Covered in Table of Content of Bone Marrow Market:

Chapter 1:Introduction,market driving force product Objective of Study and Research Scope the BoneMarrow market

Chapter 2:ExclusiveSummary the basic information of the Bone Marrow Market.

Chapter 3:Displayingthe Market Dynamics- Drivers, Trends and Challenges of the Bone Marrow market

Chapter 4:Presentingthe Bone Marrow Market Factor Analysis Porters Five Forces, Supply/Value Chain,PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5:Displayingthe by Type, End User and Region 2013-2019

Chapter 6:Evaluatingthe leading manufacturers of the Bone Marrow market which consists of itsCompetitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7:Toevaluate the Bone Marrow market by segments, by countries and by manufacturerswith revenue share and sales by key countries in these various regions.

Chapter 8 & 9:Displayingthe Appendix, Methodology and Data Source finally, Bone Marrow Market is a valuablesource of guidance for individuals and companies.

Table of Contents Continuous.

*If you have anyspecial requirements, please let us know and we will offer you the report asyou want. Thanksfor reading this article; you can also get individual chapter wise section orregion wise report version like North America, Europe, MEA or Asia Pacific.

Data Bridge set forth itself as an unconventional and neotericMarket research and consulting firm with unparalleled level of resilience andintegrated approaches. We are determined to unearth the best marketopportunities and foster efficient information for your business to thrive inthe market. Data Bridge endeavors to provide appropriate solutions to thecomplex business challenges and initiates an effortless decision-makingprocess.

Data Bridge is an aftermath of sheer wisdom and experience whichwas formulated and framed in the year 2015 in Pune. We ponder into theheterogeneous markets in accord with our clients needs and scoop out the bestpossible solutions and detailed information about the market trends. DataBridge delve into the markets across Asia, North America, South America, Africato name few.

Data Bridge adepts in creating satisfied clients who reckon uponour services and rely on our hard work with certitude. We are content with ourglorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Go here to read the rest:
Bone Marrow Market Analysis, Growth by Top Companies, Trends by Types and Application, Forecast Analysis to 2026 - Jewish Life News

Read More...

Bone Marrow Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to 2026 – TechNews.mobi

February 8th, 2020 3:49 am

The Global Bone Marrow Market study with 100+ market data Tables, Pie Chat, Graphs & Figures is now released by Data Bridge Market Research. Market definition covered in this business report studies the market drivers and market restraints with which businesses can get idea of whether to increase or decrease the production of a particular product. With the studies, insights and analysis mentioned in the report, get comprehensible idea about the marketplace with which business decisions can be made quickly and easily. The research and analysis conducted in this report helps clients to predict investment in an emerging market, expansion of market share or success of a new product with the help of Global market research analysismarket size and share of Major Players like Abbott; QIAGEN; Diazyme Laboratories, Inc.; Sanofi; CSL; STEMCELL Technologies Inc.; Lonza; HemaCare; PromoCell GmbH; Mesoblast Ltd; Lifeline Cell Technology, an International Stem Cell Company; Cellular Dynamics International, Inc.; ReachBio LLC; ATCC; Merck KGaA; Discovery Life Sciences; AllCells; ReeLabs Pvt. Ltd. and Gamida Cell.

Global bone marrow market is expected to register a substantial CAGR of 6.05% in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the rising levels of success rates with these procedures which are expected to result in higher adoption rates along with the rising levels of commercialization by the various research companies regarding their products & services.

Avail 20% Discount on Buying This Report:Get a Free Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-market&SR

Unlock new opportunities in Bone Marrow Market; the latest release from Data Bridge Market Research highlights the key market trends significant to the growth prospects, Let us know if any specific players or list of players needs to consider gaining better insights.

The study given in this section offers details of key market players. It likewise clarifies the marketing strategies adopted by these players as well as portrays their shareholdings in the global market.

How will the report help new companies to plan their investments in the market?

The market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Market Drivers

Market Restraints

And More..Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-market&SR

Why Is Data TriangulationImportantIn Qualitative Research?

This involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. Triangulation is one method used while reviewing, synthesizing and interpreting field data. Data triangulation has been advocated as a methodological technique not only to enhance the validity of the research findings but also to achieve completeness and confirmation of data using multiple methods

Key Insights that Study is going to provide:

The 360-degree overview based on a global and regional level

Market Share & Sales Revenue by Key Players & Emerging Regional Players

Competitors In this section, various industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

A separate chapter on Market Entropy to gain insights on Leaders aggressiveness towards market [Merger & Acquisition / Recent Investment and Key Developments]

Patent Analysis** No of patents / Trademark filed in recent years.

A complete and useful guide for new market aspirants

Forecast information will drive strategic, innovative and profitable business plans and SWOT analysis of players will pave the way for growth opportunities, risk analysis, investment feasibility and recommendations

This study will address some of the most critical questions which are listed below:

Get Enquiry About This Comprehensive Report @: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-market&SR

Strategic Points Covered in Table of Content of Bone Marrow Market:

Chapter 1:Introduction, market driving force product Objective of Study and Research Scope the Bone Marrow market

Chapter 2:Exclusive Summary the basic information of the Bone Marrow Market.

Chapter 3:Displaying the Market Dynamics- Drivers, Trends and Challenges of the Bone Marrow market

Chapter 4:Presenting the Bone Marrow Market Factor Analysis Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5:Displaying the by Type, End User and Region 2013-2019

Chapter 6:Evaluating the leading manufacturers of the Bone Marrow market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7:To evaluate the Bone Marrow market by segments, by countries and by manufacturers with revenue share and sales by key countries in these various regions.

Chapter 8 & 9:Displaying the Appendix, Methodology and Data Source finally, Bone Marrow Market is a valuable source of guidance for individuals and companies.

Table of Contents Continuous.

*If you have any special requirements, please let us know and we will offer you the report as you want. Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Tags: Bone Marrow MarketBone Marrow Market ApplicationsBone Marrow Market GrowthBone Marrow Market InsightsBone Marrow Market OutlookBone Marrow Market OverviewBone Marrow Market SizeBone Marrow Market TrendsBone Marrow Market AnalysisBone Marrow Market Types

Originally posted here:
Bone Marrow Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to 2026 - TechNews.mobi

Read More...

Brain links to embryonic immunity, guiding response of the troops that battle infections – Tufts Now

February 8th, 2020 3:48 am

MEDFORD/SOMERVILLE, Mass. (February 4, 2020)Researchers led by biologists at Tufts University have discovered that the brains of developing embryos provide signals to a nascent immune system that help it ward off infections and significantly improve the embryos ability to survive a bacterial challenge. Using frog embryos, which continue to develop with their brains removed, the researchers found that embryos without a brain are not able to marshall the forces of immune cells to an injury or infection site, leading the embryo to succumb to an infection more quickly. By contrast, the presence of a brain crucially helps direct immune cells to the site of injury to overcome the bacterial threat. The study was published today in NPJ Regenerative Medicine.

In a developing embryo, both brain and immune system are not fully formed. The immune system, for its part, consists mostly of an innate system of cells that respond immediately to infection and do not require training or produce antibodies. Nevertheless, these cells require signals that prompt them to move toward an infection site and trigger a response.

The research team found that the brain appears to contribute to the signals that guide the nascent immune system. When brainless frog embryos were infected with E. coli, only about 16% of embryos survived, while the presence of a brain protected more than 50% from the infection. By following markers of immune cells, researchers confirmed that the effect is not due to the missing brain somehow hampering immune system development because the composition of the immune cells remained the same with or without a brain. Instead, they found that the effect was due to the brain sending signals to the immune cells to move toward the site of an infection.

We found that macrophages innate immune system cells that can swallow up bacteria and destroy them to reduce the burden of an infection do not migrate appropriately without the presence of the brain said Michael Levin, Vannevar Bush Professor of Biology at Tufts Universitys School or Arts and Sciences and Associate Faculty at Harvards Wyss Institute, director of the Allen Discovery Center at Tufts and corresponding author of the study. Without the brain and its neurotransmitter signals, gene expression and innate immune system activity go awry, resulting in increased susceptibility to bacterial pathogens.

Other roles for the embryonic brain signaling during infection may include inducing cellular responses, for example preventing cell death or reducing inflammation, that help protect against the harmful effects of the infection.

Immune system abberations were also observed in brainless embryos that were further developed. When the researchers tracked myeloid cells, a class of immune cells that includes macrophages, neutrophils and others, after an injury, they found that the myeloid cells in brainless embryos gathered in locations far from the injury site. By contrast, myeloid cells in normal embryos with intact brains would pile up at the injury site to assist in healing. In fact, in the brainless embryo, the myeloid cells tended to cluster around abnormal, disorganized peripheral nerve networks, also a by-product of brain absence, as demonstrated in earlier studies.

An examination of aberrations in genetic expression in brainless embryos also pointed to the reduction of the neurotransmitter dopamine (a signaling chemical used in the brain for learning and motivation), and that dopamine may play a role in activating immune cells to migrate in the early stages of an infection. The absence of an immune cell quorum at the infection site leads the brainless embryos to become more susectible to its lethal effects.

Our results demonstrate the deep interconnections within the bacteria-brain-body axis: the early brain is able to sense the pathogenic bacteria and to elaborate a response targeted to fight against the cellular and molecular consequences of the infection, said Celia Herrera Rincon, Research Scientist II at the Allen Discovery Center at Tufts, and first author of the study.

Other authors of this study include: Jean-Francois Par, Christina Harrison, Alina Fischer, and Sophia Jannetty at the Allen Discovery Center at Tufts; Christopher Martyniuk, associate professor in the Department of Physiological Sciences at University of Florida; and Alexandre Dinis and Vishal Keshari, graduate students, and Richard Novak, senior staff engineer at the Wyss Institute for Biologically Inspired Engineering, Harvard Universiy.

This research was supported by the Templeton World Charity Foundation Independent Research Fellowship (TWCF0241) and the Allen Discovery Center program through The Paul G. Allen Frontiers Group (12171), as well as The Defense Advanced Research Projects Agency(DARPA, W911NF-16-C-0050), and the National Institutes of Health (AR055993, AR061988). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Herrera-Rincon, C., Par, J-F, Martyniuk, C.J., Jannetty, S.K., Harrison, C., Fischer, A., Dinis, A., Keshari, V., Novak, R., and Levin, M. An in vivo brainbacteria interface:

the developing brain as a key regulator of innate immunity. NPJ Regenerative Medicine (31 Jan 2020) DOI: 10.1038/s41536-020-0087-2

###

About Tufts University

Tufts University, located on campuses in Boston, Medford/Somerville and Grafton, Massachusetts, and in Talloires, France, is recognized among the premier research universities in the United States. Tufts enjoys a global reputation for academic excellence and for the preparation of students as leaders in a wide range of professions. A growing number of innovative teaching and research initiatives span all Tufts campuses, and collaboration among the faculty and students in the undergraduate, graduate and professional programs across the university's schools is widely encouraged.

View post:
Brain links to embryonic immunity, guiding response of the troops that battle infections - Tufts Now

Read More...

Your resistance to flu is shaped by previous flus, and their type – ZME Science

February 8th, 2020 3:48 am

How hard the flu hits us has a lot to do with our first experience of the disease, a new paper reports.

Researchers at the University of California Los Angeles (UCLA) and the University of Arizona may finally have an explanation as to why different people seem to have such different reactions to the flu. And, to a large extent, they report, it has to do with your childhood.

Our immune system often struggles to recognize and defend against closely related strains of seasonal flu, even though these are essentially the genetic sisters and brothers of strains that circulated just a few years ago, said lead author Katelyn Gostic, currently a postdoctoral fellow at the University of Chicago.

This is perplexing because our research on bird flu shows that deep in our immune memory, we have some ability to recognize and defend against the distantly related, genetic third cousins of the strains we saw as children.

An individuals ability to fight off the flu is related to the number of different flu strains they contracted during their lifetime and the order in which they did so. Prior exposure to a pathogen, be it in the wild or controlled (in a vaccine) is known as immunological imprinting.

For the study, the team set out to determine whether immunological imprinting could explain differences in how people respond to the flu. They used health records from the rizona Department of Health Services to track how different varieties of the virus affect people at various ages, focusing on the H3N2 and H1N1 strains. These strains were selected as both have led to seasonal outbreaks over the past few decades, so there was enough data on them to work from.

In very broad lines, H3N2 is more closely associated with severe flu cases in elderly people and causes the majority of flu-related deaths. H1N1 seems more partial to children and young adults and is far less deadly.

The data showed that people who were first exposed to H1N1 during childhood were less likely to require hospitalization if they re-encountered the strain later on in life compared to those who were first infected with H3N2. Similarly, this latter group would be more resistant to subsequent reinfections of H3N2.

The team looked at the evolutionary relationship between the two strains and report that they belong to two different branches of the influenza family. Further research revealed that while infection with any of the strains does somewhat boost resistance against any other, the best effects are seen with strains from the same family that an individual has battled before. Furthermore, your first exposure seems to grant you extra protection against related strains in the future: people who had their first run-in with flu as children in 1955 (N1H1 strain) were significantly more likely to be hospitalized with an H3N2 infection than an H1N1 infection when both strains were circulating.

However, the team also found that people whose first childhood exposure was to H2N2 did not have better protection when they later encountered H1N1 (although the two strains are closely related). They are still unsure as to why this is.

We hope that by studying differences in immunity against bird flus where our immune system shows a natural ability to deploy broadly effective protection and against seasonal flus where our immune system seems to have bigger blind spots we can uncover clues useful to universal influenza vaccine development.

The paper Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics has been published in the journal PLOS Pathogens.

See original here:
Your resistance to flu is shaped by previous flus, and their type - ZME Science

Read More...

Woman mocked for wearing face mask amid fears of coronavirus. She has cancer. – KHOU.com

February 8th, 2020 3:48 am

HOUSTON, Texas Angely Roman Ithier came to Houston from Puerto Rico for cancer treatment.

She's been cooped up for months so when her brother came to visit, she was excited about their road trip to San Antonio.

But a gas station pit stop along the way cast a shadow on the rest of the trip.

It was very hurtful," Angely said.

At first glance, you'd never guess anything is wrong with Angely. But if you take time to know her, you'd learn her backpack is feeding her medication and her pixie cut is a wig.

The only thing that sets her apart is the mask she wears as a precaution because the cancer treatment lowers her immune system.

RELATED: Japan finds 41 more coronavirus cases on cruise ship as death toll rises in China

RELATED: Chinese doctor who raised alarm on coronavirus dies from the illness

They recommend me, anytime I go outside where theres a lot of public, I wear a face mask because I can not get any flu or symptoms," Angely explained.

A couple inside the gas station assumed Angely was wearing the mask because of fear over the coronavirus. She overheard them laughing and making fun of her.

Right at that moment, he passed by and he went 'achew,' and he sneezes and I was like, 'what?' Angely said.

She said the couple pretended to sneeze on her.

Just ignorant that they just think she was trying to avoid the coronavirus, without actually knowing why she was wearing a face mask," Angely's brother Ricardo Roman Ithier said.

"Then I just went to her and I said, 'You know what? You know why I wear a face mask? Because I have cancer,'" Angely said.

And they just left. They didnt want to, like, get into a confrontation so they just like avoided the whole thing," Ricardo said.

Then, the anger turned to pain.

Every day, we struggle with our mind and how we feel and to go outside, and to be exposed to that kind of jokes, it's not funny. Nobody deserves that," Angely said. I felt ashamed of going out because you feel different, and I do all the time."

To me, it really got me frustrated, just seeing her cry," Ricardo said.

Angely said even if she she didn't have cancer and was worried about getting Coronavirus, the jokes and judgment were unkind.

Treat people with respect but also be kind to people. You dont know how that person woke up that morning," Angely said. "You dont know what a person is going through."

RELATED: Chicago husband, wife sickened by coronavirus leave hospital

RELATED: 10 more sick with coronavirus on cruise ship in Japan

RELATED: Chinese baby tests positive for coronavirus just 30 hours after birth

RELATED: Back from China without coronavirus symptoms, Houston man self-isolates

RELATED: A 'virus hunter' at UTMB Galveston explains the challenges of controlling coronavirus

RELATED: Professor: Coronavirus to impact Houston's economy

Read more from the original source:
Woman mocked for wearing face mask amid fears of coronavirus. She has cancer. - KHOU.com

Read More...

Communication, Caution Urged in Response to Coronavirus at YSPH Forum – Yale News

February 8th, 2020 3:48 am

A panel of Yale experts did their best to explain the current threat and future direction of the novel coronavirus epidemic during a forum Thursday hosted by the Yale School of Public Health. But they frequently cautioned the standing-room-only crowd that there is much about the mysterious illness that simply remains unknown.

Preliminary indications are that the virus is not as contagious as measles, is comparable in many ways to SARS (Severe Acute Respiratory Syndrome that resulted in 774 deaths worldwide in 2003) and is worse than the flu. But even these assessments could change as new data emerges, said moderator Saad Omer, director of the Yale Institute for Global Health and Susan Dwight Bliss Professor of Epidemiology at the Yale School of Public Health.

You shouldnt be walking around in a spacesuit on College Street, its reasonable to say that, Omer told the gathering of some 120 students and faculty in Winslow Auditorium. On the other hand, we dont know the future risks of this outbreak.

More than 30,000 people have been sickened since the virus first appeared last December and more than 600 people have died. The respiratory illness has appeared in 28 countries but is most prevalent in China. While patients with the virus have been reported in the United States, there have been no reported infections in Connecticut.

In response to the outbreak, stockpiles of protective masks have sold out in parts of China. Panelist Lisa Sanders, an associate professor at the Yale School of Medicine, said there is no evidence that wearing a face mask offers protection.

The best way to prevent getting the virus, Sanders said, is to adopt the same precautions used for avoiding the flucough into your elbow, avoid people who have an obvious infection, self-quarantine if you have symptoms, and wash your handsthoroughly and often.

If people just washed their hands a little bit more that would go a long way, said Sanders, who is also an Emmy-award winning television producer and writes the Diagnosis column for the New York Times.

Given the similarity of coronavirus to the flu, some have questioned why this particular respiratory illness is raising so much concern. Ellen Foxman, assistant professor at the Yale School of Medicine, explained that it is new to humans.

When our body fights a virus, it activates an immune response to block it and that response can be called on again should the virus return, Foxman said. Without that pre-existing defense, it is easier for a new virus to spread from person to person.

Thats why a new virus is always cause to be alert, to be vigilant, Foxman said. Just because its new doesnt mean its worse than other viruses, but there is that potential and thats why there is reason to be vigilant about it.

With so many uncertainties surrounding the virus, the panelists said it is vital for officials to be clear about what is known and unknown when publicly sharing information. Scientists have been quick to share information about the virus as it becomes available to aid in the international response. But that process can be problematic, particularly when findings are released before vetting.

When you have an emerging outbreak there is uncertainty and we should acknowledge that uncertainty, said Omer. We certainly know a lot more about this outbreak than before, but we owe it to the public to convey what we dont know.

In order to avoid misinformation during an outbreak, Omer said a rapid peer review system needs to be created so that other scientists can quickly evaluate information before it is released publicly. He said universities could play an important role.

One thing that is certain is that the virus was not released from a Chinese laboratory, despite such rumors circulating on social media, said Nathan Grubaugh, an assistant professor at the Yale School of Public Health. Coronavirus most likely originated in bats. While the virus also appears to be mutating over time, that is part of its natural evolution and does not necessarily mean it is becoming more deadly, he said.

Whether this is going to be SARS or the common old, we just cant look at the virus genome and determine that, said Grubaugh. We dont have enough data right now to say how bad it is going to be.

Uncertainties surrounding transmission of the virus have led to drastic action in some areas. It was reported Thursday that a Chinese health official had ordered the city of Wuhan, where the virus first appeared, to place all infected residents in mass quarantine camps.

Yale Nursing Professor David Vlahov, who has a joint appointment in epidemiology and public health, voiced his concern that such quarantines could hinder public health efforts and have a stigmatizing effect, forcing people underground.

Gregg Gonsalves, an assistant professor at the Yale School of Public Health and co-director of Yales Global Health Justice Partnership, said he is particularly concerned about human rights issues as the virus spreads.

When considering quarantines, officials must use the least restrictive measures possible and not overreact, said Gonsalves, an adjunct associate professor at Yale Law School. Gonsalves is part of a legal team that is suing Connecticut for quarantines during the 2014 Ebola outbreak.

Were thinking about risks to the United States, but think about the thousands of Chinese patients with coronavirus whose health status is going to be put into a precarious position if they are isolated into these facilities, said Gonsalves.

Should the virus establish a stronger foothold in the United States, Omer said he hopes the greater Yale community will respond appropriately.

Outbreaks can bring out the best and the worst in people, Omer said. It is extremely important that we treat each other with dignity, respect and compassion.

When asked what the latest scientific estimates were for the virus to peak and eventually end, the panelists said it is simply still too early to tell. Professor Albert Ko, chair of the Yale School of Public Healths Department of Epidemiology of Microbial Diseases, said the epidemic is still growing in its exponential phase. Ko said he is concerned about vulnerable populations in countries that dont have significant health care resources.

On a more positive note, Vlahov said the current crisis could be an impetus for more public health funding. But Yale School of Public Health Dean Sten Vermund said funding support for public health is always a challenge.

Its hard to convince policymakers to pay you to do something to prevent something from happening, Vermund said. Its much more intuitive to invest in hospitals to care for the ill, then it is to invest in public health infrastructure to prevent the illness to begin with.

A recording of Thursdays forum can be viewed here.

View post:
Communication, Caution Urged in Response to Coronavirus at YSPH Forum - Yale News

Read More...

Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer – Xconomy

February 8th, 2020 3:48 am

XconomySan Francisco

Cell therapies have reached the market as a new treatment option for some cancers. But the scientists of Sonoma Biosciences say this approach also holds promise for autoimmune disorders, and the biotech startup has unveiled $40 million in financing to develop its technology.

The investors in Sonomas Series A round of funding include Lyell Immunopharma, ARCH Venture Partners, Milky Way Ventures, and 8VC.

Cell therapy involves removing a patients immune cells, engineering them, and then infusing them back into the patient to perform their therapeutic tasks. The cancer cell therapies that have been approved by the FDA are made by engineering T cells, the frontline defenders of the immune system.

Sonoma, which splits its operations between South San Francisco and Seattle, is working with a different immune cell called a regulatory T cell (Treg). Whereas T cells target pathogens, Tregs target other immune cells, suppressing excessive immune responses, CEO and co-founder Jeff Bluestone tells Xconomy. Research by Sonomas scientific co-founders uncovered evidence, in studies in mice and humans, that the absence of these cells sparked the development of some autoimmune diseases. Those diseases led to death in about one year without a bone marrow transplant, Bluestone adds.

Sonoma is developing Treg therapies intended to shut down unwanted immune responses. The approach involves harvesting these cells from patients and engineering them with features that make them stable, durable, and targeted specifically to the site of inflammation. Those cells would then be infused into the patient to stop the autoimmune response. Bluestone says its too soon to talk about a lead disease target, but he adds that this approach has potential applications in rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.

The hope is that a Sonoma cell therapy is a one-time treatment. Bluestone says that because these therapies are cells that multiply, they should survive in the patient on standby until theyre needed again to address an autoimmune response.

Theres another feature that could contribute to the longevity of a Treg treatment. When these cells shut down an autoimmune response, they influence other cells in the vicinity to join in, Bluestone explains. By educating these other cells to take up this immunosuppressive role, Bluestone says the effect of these therapies could be long lasting. But he cautions that the durability of a Treg therapy wont be known until more tests are done in humans.

Bluestones knowledge about Tregs stems from his own research. He and another Sonoma co-founder, Qizhi Tang, studied Tregs at the University of California, San Francisco, for 12 years. Their research included diabetes, organ transplantation, and lupus, among other conditions. That work led to small patient studies testing the technology for safety.

In addition to his UCSF research, Bluestone was the president and CEO of the Parker Institute for Cancer Immunotherapy. Over the course of a career that has bridged academia and industry, Bluestones immunology research has led to the development and commercialization of immunotherapies for organ transplants and cancer. He says he is joining Sonoma now because theres only so far that you can get in an academic lab if you want to impact peoples lives. Cell therapy could be the next major medicine for humans, he adds, and he wants to be involved as part of a company developing these treatments.

The other co-founders are Chief Scientific Officer Fred Ramsdell who, like Bluestone, joined Sonoma from the Parker Institute, and Alexander Rudensky, an immunologist at the Memorial Sloan Kettering Cancer Center. Ramsdell and Rudensky are credited as co-discoverers of the FOXP3 gene that is critical to the development and function of Tregs.

Bluestone says that Sonoma continues the Treg research that he and the other co-founders had done. The company also builds on the successes and failures in cancer cell therapy research. While those therapies can treat blood cancers, its been much harder to use them to treat solid tumors. Bluestone hopes that Lyell, a South San Francisco cell therapy company, can help the company get its therapies into tissues. In addition to being a Sonoma investor, Bluestone says Lyell will be a research partner, providing access to its technology and cell therapy insights.

Sonoma also aims to go beyond autoimmune diseases. Bluestone says the companys approach could potentially address degenerative disorders, such as amyotrophic lateral sclerosis and Alzheimers disease. In the nearer term, Bluestone says the company will use the funding to better understand Tregs.

The way were approaching this field is not to be in a hurry, in a sense of feeling this pressure or need to get into the clinic with these engineered cells as quickly as possible, he says. We want to spend the time to make sure were working with the best cells possible, that we understand the science and the biology, so that it has the best chance of success.

Public domain image by Flickr user NIH Image Gallery

Frank Vinluan is an Xconomy editor based in Research Triangle Park. You can reach him at fvinluan [[at]] xconomy.com.

View original post here:
Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer - Xconomy

Read More...

High Levels of PFAS Affect Immune, Liver Functions in Cape Fear River Striped Bass – NC State News

February 8th, 2020 3:48 am

Researchersfrom North Carolina State University have found elevated levels of 11 per- andpolyfluoroalkyl (PFAS) chemicals in the blood of Cape Fear River striped bass.Two of those compounds perfluorooctane sulfonate (PFOS) and Nafion byproduct2 are associated with altered immune and liver functions in those fish.

Scott Belcher, associate professor of biology and corresponding author of a paper describing the research, led a team that included NCState colleagues Detlef Knappe, Ben Reading and postdoctoral researcher Theresa Guillette as well as partners from the North Carolina Wildlife Commission and the U.S. Environmental Protection Agency (EPA).

Theteam isolated serum from the blood of 58 wild caught Cape Fear River stripedbass ranging in age from 2 to 7 years old. In collaboration with EPA researchersMark Stryner and James McCord, they determined the concentrations of 23different PFAS chemicals present in the serum using a combination of liquidchromatography and high-resolution mass spectrometry.

Testingblood levels gives you an idea of the body burden of these particularchemicals, Belcher says. The levels of these chemicals in the water weremeasured in parts per trillion, but in the serum of the fish levels are higherand in parts per billion, demonstrating that they have clearly bioaccumulatedin these fish.

Theteam then compared the blood serum samples from the wild caught fish to thosefrom a reference population of 29 striped bass raised in an aquaculturefacility fed by ground water. The serum levels of chemicals in the wild caughtbass were 40% higher, on average, than the background levels found in thisreference population, Belcher says.

Incomparison to the levels of PFAS found in Cape Fear River water, elevatedlevels of PFOS and Nafion byproduct 2 were found in 100% and 78% of the wildbass samples, respectively. The serum concentrations of these compounds wereassociated with biomarkers of altered liver enzyme activity and immune functionin those fish.

ThesePFAS levels are some of the highest recorded in fish, Belcher says, but oneof the most unusual findings here is that smaller or younger fish had thehighest levels of these compounds. This points to the fact that PFAS chemicalsare very different from other persistent chemicals, like mercury or PCBs. Theyhave unique and very different chemical properties that cause them tobioaccumulate differently, and were really just beginning to understand whyand how they do what they do.

The work appears in Environment International, and was supported in part by the National Institute of Environmental Health Sciences (award numbers P30ES025128 and R21ES029353), and a North Carolina Sea Grant Community Collaborative Research Grant. Theresa Guillette is first author. Matthew Guillette, M.E. Polera and Nadine Kotlarz from NCState, as well as Kyle Rachels and Clint Morgeson from the N.C. Wildlife Resources Commission, also contributed to the work.

-peake-

Note to editors: An abstract follows.

ElevatedPer- and Polyfluoroalkyl Substances in Cape Fear River Striped Bass (Morone saxatilis) are Associatedwith Biomarkers of Altered Immune and Liver Function

DOI: 10.1016/j.envint.2019.105358

Authors: T.C. Guillette, Matthew Guillette, M.E. Polera, NadineKotlarz, Detlef Knappe, Benjamin J. Reading, Scott Belcher, North CarolinaState University; James McCord, Mark Strynar, National Exposure Research Laboratory,ORD, U.S. EPA, Research Triangle Park, North Carolina; Kyle Rachels, ClintMorgeson, N. C. Wildlife Resources Commission, Inland Fisheries DivisionRaleigh, NC

Published: Feb. 7 in Environment International

Abstract:Per- and polyfluoroalkyl substances (PFAS)are anthropogenic chemicals of concern that persist within the environment.Environmental monitoring revealed high concentrations of hexafluoropropyleneoxide dimer acid (HFPO-DA) and other novel PFAS in the lower Cape Fear River;however, there is limited information on PFAS exposures and effects of thiscontamination on aquatic biota. Serum concentrations of 23 different PFAS inStriped Bass (Morone saxatilis) fromthe Cape Fear River (n=58), and a reference population from an aquaculturelaboratory on the Pamlico/Tar watershed (n=29), were quantified using liquidchromatography, high-resolution mass spectrometry, and correlations betweenPFAS concentrations and health-related serum biomarkers were evaluated.Perfluorooctane sulfonate, the predominant PFAS in Cape Fear River Striped Bassserum, was detectable in every sample with serum concentrations reaching 977ng/mL. Perfluorononanoic and perfluorodecanoic acid were also detected in allsamples, with perfluorohexanesulfonic acid present in >98% of the samples.HFPO-DA (range <0.24-5.85 ng/mL) and Nafion byproduct 2 (range <0.21.03ng/mL) were detected in 48% and 78% of samples, respectively. The mean totalPFAS concentration found in domestic Striped Bass raised in well-water under controlled aquacultureconditions was 40 times lower, with HPFO-DA detected in 10% of the samples, andNafion byproduct 2 not detected. The elevated PFAS concentrations found in theCape Fear River Striped Bass were associated with biomarkers of alterations inthe liver and immune system.

Read more here:
High Levels of PFAS Affect Immune, Liver Functions in Cape Fear River Striped Bass - NC State News

Read More...

The Coronavirus Started in Animals. That Makes it More Dangerous. – Futurism

February 8th, 2020 3:48 am

The coronavirus that emerged in China and rapidly spread around the world almost certainly jumped to humans from an animal. While thats certainly not unheard of, scientists are on high alert because zoonotic viruses, as theyre called, can potentially be more dangerous.

The heightened risk associated with animal-borne diseases like 2019-nCoV comes from the fact that our immune systems have never had the chance to build up resistance to them, according to New Scientist.

From an evolutionary perspective, a successful virus is one that develops to spread rapidly and rampantly something that depends on the survival of its host.

They dont want you to drop dead within a day because you wont pass it to anyone else, University of Nottingham researcher Chris Coleman told New Scientist.

Recent research in the journal Nature suggests that the coronavirus emerged in bats rather than an earlier snake hypothesis.

In either case, its cause for concern. When zoonotic viruses jump to humans, they can be far more deadly than they were in their animal host because theyveadapted to that animals immune systemrather than ours.

Thus far, the coronavirus outbreak has had a lower fatality rate than other zoonotic diseases, New Scientist reports, but its particularly adept at spreading among humans.

But to fight deadly outbreaks in the future, Coleman stressed the value of preparing broad-spectrum vaccines in advance something still missing for the coronavirus.

See the original post here:
The Coronavirus Started in Animals. That Makes it More Dangerous. - Futurism

Read More...

3 Canadian Biotechs to Consider Buying Today – The Motley Fool

February 8th, 2020 3:48 am

Innovation knows no borders allowing adventurous biotech investors the opportunity to find hidden gems located outside the major research and development hubs in the U.S., Europe, and Japan. One doesn't even need to look too far.

Here we previewthree such companies hailing from Canada, specifically the greater Vancouver area, which boastpromising drugs in their pipelines and just raised additional financing from savvy insitutional investors eager to get ahead of the curve. These emerging biotechs may be the ticket for risk-tolerant investors to boost their portfolios.

Image source: Getty Images.

Biotech investors are taking note of Vancouver-based Zymeworks (NYSE:ZYME). In the last year, the stock steadily tripled from $15 to its current price of $46. Last week, the company announced it successfully raised $320.8 million, primarily from institutional investors.

Zymeworks engineers antibodies, a component of the immune system, to selectively recognize distinct targets on cancer cells. Each molecule can identify two separate targets leading to their name bispecific antibodies. Zymeworks did not stop there. In some cases, the company attaches highly potent cancer-killing drugs to the bispecific molecule using it as a targeting system. This is called an antibody drug conjugate and potentially increases the ability to kill cancer cells.

One of many companies battling breast cancer, Zymeworks initially began development against a set of aggressive cancers that contain the human epidermal growth factor receptor 2 (HER2) gene. The HER2 gene helps regulate cell division, growth, and repairs. Aberrant amounts of the gene can lead to excessive growth of cancer cells. Beyond breast cancer, HER2 overexpression or amplification is found in certain cancers of the stomach, pancreas, and salivary gland, to name a few.

Lead compound ZW25 targets two unique variants of HER2, and has entered a slate of human clinical trials. The antibody drug conjugate version called ZW49 is in early stage clinical trial testing.

A review of Zymeworks' pipeline shows a long list of drug candidates being developed in collaboration with other companies. These include pharma stalwarts Eli Lilly, Merck, Bristol-Myers Squibb, Johnson & Johnson, and emerging China-based pharma BeiGene.

Targeting neurological disorders, Xenon Pharmaceuticals (NASDAQ:XENE) recently raised an additional $60 million in financing to advance its pipeline. This comes on the heels of receiving $50 million from a new partnership. This capital infusion should provide enough resources to advance its four clinical stage drug candidates forward.

Xenon plans to advance XEN496 into a pivotal phase 3 clinical trial for a rare and severe form of childhood epilepsy. Towards the end of 2020, the company expects results from a phase 2b trial with XEN1101 as a treatment for adults with focal epilepsy. In this disease, recurring seizures emerge from a specific part of the brain.

Like Zymeworks, Xenon boasts prominent strategic partners. Genentech, part of the Roche Group, forged a collaboration to pursue a novel approach to treating pain. Following an initial discovery collaboration, Merck acquired the rights to a compound as a treatment for cardiovascular disease.In September, Xenon entered a partnership with biotech Flexion Therapeutics to develop an extended-release thermosensitive hydrogel version of Xenon's XEN402 for post-operative pain.

Last December, Neurocrine Biosciencesentered into a partnership to develop novel epilepsy treatments. The pact grants rights to Xenon's clinical-stage epilepsy drug XEN901 and a multi-year collaboration to discover new drug candidates. Neurocrine paid $50 million consisting of $30 million in cash and a $20 million equity investment. Xenon could potentially earn development, regulatory, and commercial milestones totaling approximately $1.7 billion for XEN901 and other collaboration programs.

Last December was a whirlwind for Aurinia Pharmaceuticals (NASDAQ:AUPH). First, the company announced positive results from a phase 3 clinical trial of its drug voclosporin in lupus nephritis, a dangerous kidney disease caused by the body's immune system attacking healthy tissues. The company plans to file for approval with the U.S. Food and Drug Administration sometime in the first half of 2020. Aurinia plans a commercial launch of the product, assuming approval, in the first half of 2021.

Investors excited by the trial results drove up the stock price from the $5 range to the high teens. When the stock was in the $18 range, management at Aurinia opportunistically raised $191.7 million at $15 per share. With more money in the bank, investors clamored for the stock pushing the shares to $21, a four-fold gain from where the stock traded prior to the clinical trial results.

Beyond lupus nephritis, Aurinia has commenced clinical testing of voclosporin in dry eye syndrome and focal segmental glomerulosclerosis (FSGS). Chronic in nature, the hallmarks of dry eye syndrome are irritation and inflammation. FSGS, a rare disease that attacks the kidneys' filtering system and can be potentially life-threatening, has no FDA-approved treatments.

Zymeworks feels like Seattle Geneticsin its earlier days. Leveraging expertise in a core technology, it produced a broad array of wholly owned and partnered drugs. Investors should watch for clinical results from ZW25 and ZW49. With a $2 billion valuation, a big pharma or biotech could swoop in to pick up this promising biotech.

Xenon, the smallest of the three companies by market capitalization, really needs the top-line results with XEN1101 in epilepsy to be positive. The trial results are expected in the second half of the year. While investing in R&D stage biotech is risky, Xenon needs to deliver more data to provide investors more comfort.

As a single-product company, Aurinia appears to be a likely acquisition target in the rare disease space. Voclosporin faces competition from GlaxoSmithKline, but, perhaps, a company like Pfizer, which has its own program in FSGS, could be a suitor.

Read the original:
3 Canadian Biotechs to Consider Buying Today - The Motley Fool

Read More...

Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? – Genetic Literacy Project

February 8th, 2020 3:47 am

In 1923,Frank Silver and Irving Cohn publisheda song that became a major hitfor the Billy Jones Orchestra, with thesignature line Yes, we have no bananas; we have no bananas today. It turned out to be sadly prophetic as, in the 1950s, the banana trees that supplied the entire global banana export business were wiped out by a soil-borne fungal diseaseknown asPanama Wilt.

The industry at that time was almost entirely based on a single banana cultivar called Gros Michel (meaning Big Mike), and it was susceptible to infection by a strain of fungus called Fusarium. Once the soil of a given plantation was contaminated with that strain, any Gros Michel tree grown there would soon die.

By good fortune, a different banana cultivar that was being grown in the South Seas was able to substitute for Gros Michel as a commercial line, and this new Cavendish cultivar became the new banana of international commerce, as it remains to this day. (Check out this interesting blog post about the history of the Cavendish variety and how it actually passed through a greenhouse in England in that process! And here is another good post about the history of this disease and the industry.)

Unfortunately, its about time for some band to cover Yes, We Have No Bananas because, evolution being what it is, a new strain of Fusarium Tropical Race 4 has arisen and it is lethal to the Cavendish. The disease is slowly making its way around the world, and since it can be spread in a particle of dirt on something like a boot, it will almost inevitably make it to the Central and South American growing regions that supply both North America and Europe with their bananas.

Although this unfortunate scenario has been on the minds of the banana industry for decades, it is now starting to get more attention in the mainstream press. One part of the story that has been shocking to these outside observers is that such a huge industry would ever be dependent on a single cultivar of banana. As Stephen Mihm put it for Bloomberg, this looming bananapocalypse is attributable to a vulnerability that comes from the practice of extreme monoculture.

While I understand why observers might be shocked that a nearly $12 billion industry depends almost exclusively on the Cavendish banana, I do want to push back on the implied conclusion that this represents some sort of irrational or irresponsible expression of big ag or whatever other demons are imagined by the Food Movement.

When you see something that is a standard practice in a very large, nationally diverse and multi-company business like bananas, I would suggest that it is appropriate to ask not what is wrong with this system but rather, What are the practical factors that drive this seemingly irrational practice?

Im not a banana expert, but in the mid-1990s, two of my first jobs as an independent consultant had to do with the banana industry. It was during the exciting early years of commercial plant biotechnology, and many industries were asking, What might this new technology do for our business? Both of my projects involved early-stage discussions between a major banana company and a plant biotech company four different entities in all. These were drawing board stage projects, with the goal of figuring out if certain ideas could ever make economic sense: Would they be something worth years of effort and millions of dollars for research?Still, overall, biotechnology looked like a way for this industry to tap into genetic diversity.

The fun part for me was getting to do a deep dive into the details of how bananas are grown, handled, shipped and marketed. I got to travel to Honduras, Costa Rica and Ecuador to tour banana plantations and interact with experts at the major banana export companies. As I said, Im not an industry insider, but I think I can shed some light on why there are not more kinds of bananas grown for export.

As modern consumers, we are offered an amazingly diverse selection of fresh fruits and vegetables year-round, so it is important to think back to the early days of this offer of plenty. Having grownup in Denver in the 1960s, I can recall that, except for a few summer months, almost the only fresh fruit options at the grocery store were bananas, apples and oranges. I have a podcast aboutwhy apples were ever on that list. But if you think about it, the very fact that we can so easily enjoy fresh bananas in temperate regionsis a bit remarkable.

Bananas can grow only in regions where there is never frost, and they do best in truly tropical climates. How did a tropical fruit become a mainstream, reasonably priced, healthful, kid-popular fruit for people who experience winter?

In tropical regions, there is a great deal of genetic diversity among wild bananas and considerable diversity among the banana or plantain types that humans cultivate. However, very few of these bananas could ever meet the criteria needed to be a viable export crop.

First of all, a banana for export has to be seedless. Many wild bananas have large, very hard black seeds not something that has much consumer appeal. The bananas that people like are seedless because they have triploid genetics three of each chromosome vs. the two that we have. That is the same way we get seedless watermelons, grapes, etc. Its not some GMO thing; it happens at times in the plant kingdom, and we humans like it! Still, improving or changing the cultivar through conventional breeding isnt an option if it makes no seeds.

Next, the banana needs to be productive in terms of overall yield per tree or acre. Im sure no one in the 1920s was calculating it, but in modern sustainability thinking, the land-use efficiency of a crop is an important criterion. That, along with water-use efficiency, small carbon footprint and energy footprint,is all very much tied to good yield. The usable per-hectare yields of the Cavendish variety are quite high, and that is why it has been a both economically viable and environmentally sustainable choice for a long time.

But probably the most limiting requirement for a banana variety to be commercially acceptable is thatit has to be shippable. In the modern era, we have lots of transport options for food products, but during the era when the banana was becoming an item of international trade, the only viable option was ocean shipping. A product being moved from the tropics to North America or Europe needed a very-low-cost transport option if it was ever going to be a mainstream consumer product. Most fresh produce products loaded onto a ship for a two-plus-week trip to a northern port would be a soup of decay by the time they arrived.

What made the Gros Michel and its successor, the Cavendish, remarkable was that they could make that trip at a temperature range of 55-58 degrees Fahrenheit, and so not even require lots of energy for refrigeration. Very few of the wonderful range of cultivated or wild banana types could ever do that, but because the Cavendish can be shipped this way, the energy and carbon footprint ofits shipment is small. This crop has a very attractive food-miles profile.

In addition,it turns out that the conditions under which bananas grow can affect their shipping potential. There is a disease that infects only the leaves of banana plants called Black Sigatoka. If a banana tree has suffered too much of that infection, even the robust Cavendish variety wont be able to make the trip by sea. One thing I learned on my tour was that plantations have employees whose whole job is to survey the plantation on a tree-by-tree basis in order to qualify the fruit for shipment based on how well that disease has been managed.

But it gets even more complicated than that (heres a good video summary of the process). Bananas are picked in Central and South America at a green stage imagine a fruit more completely green than the greenest one youve ever seen in the clusters in your store. When they get to their destination, they are put into ripening rooms, where they are exposed to ethylene gas to start them on the way to the ripe yellow fruit you know. Before you freak out, know that ethylene is the fully natural plant hormone that induces ripening in most fruits and vegetables.

There is a definite art to this ripening process, and highly valued experts who can assess each shipment of bananas know just how to handle them in the ripening rooms to achieve the goal of delivering just right bananas at retail. This process has to factor in issues like ups and downs in demand and turnover rates at key retail customer outlets, in addition to the condition of the incoming fruit.

I know that at the stores where I shop, I can consistently buy bananas that are close to ripe but not fully, such that I can hope to consume them all before they turn black. We consumers might think we have a balancing act to do when it comes to timing ripening and consumption of the bananas from our counters, but imagine that on a huge scale for the banana distribution chain.

There is one more critical element of the business model: Those ships that come to our ports loaded with bananas certainly cant go back empty. The banana shipping companies are also seriously involved in their back-haul business of bringing back products of interest in the source countries. Having a well-understood, predictable crop helps with running that business efficiently as well.

So for the international banana business to work in a way that provides a relatively low-cost product acceptable to consumers, it needs to be able to function in a reliable and predictable fashion. Figuring out how to do this with a new banana variety would be a huge challenge. How do you grow it efficiently? Can the crop make the trip reliably? How can its ripeness be managed in order to meet both the distribution chain requirements and the needs of consumers for decent counter life? Will all of this work in a way that is compatible with a viable back-haul business?

So while it is easy to think that the banana industry is crazy to depend on one cultivar, Isubmit to you thatit is not without reasonand it implies noirresponsibility.

So does that just mean that we are inevitably going to live out the unintended prophecy of yes, we have no bananas? I think that depends on whether we continue to live in a world where anti-biotechnology groups are able to exercise the control that they currently have over our food system.

Let me explain. Remember that my introduction to bananas was based on excitement about what biotechnology could do for the crop. One of the concepts was to develop bananas that were resistant to that leaf infection disease that can compromise ship-ability. Control of that disease requires something like 40 fungicide sprays a year, so as you can imagine, there would be a huge cost savings if the trees could be made resistant.

The other concept on the table was modifying the banana so that it would stay in that nice yellow, but not yet black, stage longer on the consumers counter. Ill never forget that in the first meeting about that idea, a participant who worked for a UK-based banana importer said in his very British accent: Why would you want to do that? Dont you know that the dustbin is a major consumer of bananas? Obviously, he wasnt attuned to current sensitivity to the need for food waste reduction. I thought it was cool that a banana company was serious about an idea that might reduce food waste, with the hope that it would make consumers more comfortable about buying even more bananas.

Well, these were just theoretical ideas at the time, and they didnt go anywhere because it soon became evident that the anti-GMO forces were quite successful at putting brand-sensitive companies in an untenable spot if they were using GMO crops not just for generic ingredients but for brand-central crops.A dramatic examplewas how fast-food chains like McDonalds moved to avoid biotech potatoes for their signature fries.

It quickly became clear to the banana companies that their brands and their retail store access could be compromised if they pursued GMO options. The irony here is that this would have been the most viable strategy with which to bring genetic diversity into the logical but extreme monoculture of bananas.

Sothe irony is that if the yes, we have no bananas scenario becomes a reality, it will be because we as a global society didnt use a safe, viable, scientifically sound strategy torationally deal with the problem in the banana crop.

Public institution scientists in Australiaand entrepreneurial scientists in Latin America have come up with ways to modify commercially relevant bananas to resist the Fusarium disease. Ideally, there would be the potential to use several approaches, either in the same banana or in different fields; that wouldavoid delay selection for resistance and avoid yet another dependency on a single line. It is likely that the heritage variety Gros Michel could be made commercially viable once again!

If the Fusarium-resistant biotech bananas were introduced, activists would almost certainly attack them as GMO.Would any of the big banana companies have the guts to move forward with the technology in spite of the inevitable brand attacks by NGOs?Would any big food retailers be willing to resist the inevitable pressures not to stock that fruit? That retail blockage strategy is being used today against other new biotech offerings such asnon-browning applesandpotatoesandfast-growing, terrestrially raised salmon.

At one level, this is a question about what will be available for us as consumers. Will we continue to have this highly consumed, reasonably priced, child-friendly, healthy food option? Maybe not. But there is another big question.

One thing I witnessed on those visits to the banana industry back in the 90s was that large communities in Central and South America flourish because of the jobs that this industry creates. We in the rich world will still have lots of other fruit choices if the stores have no bananas, but that flexibility isnt there for the familiesthat have been doing the work to provide us with this staple food option for so many decades.

I would think that most activists are the kind of people who care about the availability of healthy, low-cost fruit options; I doubt that they would want to see the banana-producing communities impoverished. However, if the current paradigm of anti-GMO intimidation of fruit companies and retailers continues, that is where we are headed.

A version of this story originally ran on the GLP on April 16, 2018.

Steve Savage is a plant pathologist and senior contributor to the GLP. His Pop Agriculture podcast is available for listening or subscription on iTunes and Google Podcasts. Follow him on Twitter @grapedoc

Go here to read the rest:
Viewpoint: Biotechnology could save our favorite banana. Will anti-GMO activists stand in the way? - Genetic Literacy Project

Read More...

Researchers identify roots of childhood asthma – European Biotechnology

February 8th, 2020 3:47 am

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

The discovery of a team headed by Hans Bisgaard at Gentofte Hospital in Gentofte, Denmark, reveals that childhood asthma is closely intertwined with the behaviour of the immune system early in life a finding that could open the door to new diagnostics and preventative strategies.

The immune system develops as immune cells begin to respond to different types of microbes from the environment. This early stage of development is critical: any persistent abnormalities can trigger chronic inflammation and may raise the risk of asthma and other allergic diseases.

To flesh out the connection between early-life immunity and asthma, first author Anna Thysen et al. studied a longitudinal cohort of 541 children, by analysing blood samples collected at 18 months and comparing these immune profiles to clinical outcomes at six years of age. The scientists exposed blood cells gathered from the 18 month olds to different molecules from viruses, bacteria and fungi. They observed that neutrophils of the innate immune system from some infants responded too strongly to certain viruses, and these same infants were more susceptible to transient asthma as they approached the age of six. Furthermore, some infants harboured T cells that produced excessive amounts of IL-5 and IL-13 two pro-inflammatory cytokines associated with asthma and were more likely to have developed persistent asthma at six years of age.

Thysenet al.speculate that future blood tests to detect abnormal immune signatures in infants might allow for earlier prevention or treatment of childhood asthma.

See the original post:
Researchers identify roots of childhood asthma - European Biotechnology

Read More...

Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? – InvestorsObserver

February 8th, 2020 3:47 am

The 66 rating InvestorsObserver gives to Esperion Therapeutics Inc (ESPR) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 85 percent of stocks in the Biotechnology industry, ESPRs 66 overall rating means the stock scores better than 66 percent of all stocks.

Click Here to get the full Stock Score Report on Esperion Therapeutics Inc (ESPR) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Esperion Therapeutics Inc (ESPR) stock has gained 7.95% while the S&P 500 has fallen -0.25% as of 11:33 AM on Friday, Feb 7. ESPR has gained $4.61 from the previous closing price of $57.98 on volume of 444,201 shares. Over the past year the S&P 500 is higher by 23.33% while ESPR has gained 38.57%. ESPR lost -$3.69 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

See the article here:
Industry Analysis: Should You Buy Esperion Therapeutics Inc (ESPR) in Biotechnology? - InvestorsObserver

Read More...

Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE – Simply Wall St

February 8th, 2020 3:47 am

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. To keep the lesson grounded in practicality, well use ROE to better understand Avecho Biotechnology Limited (ASX:AVE).

Over the last twelve months Avecho Biotechnology has recorded a ROE of 2.5%. One way to conceptualize this, is that for each A$1 of shareholders equity it has, the company made A$0.03 in profit.

Check out our latest analysis for Avecho Biotechnology

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) Shareholders Equity

Or for Avecho Biotechnology:

2.5% = AU$158k AU$6.2m (Based on the trailing twelve months to June 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders equity is a little more complicated. It is all earnings retained by the company, plus any capital paid in by shareholders. The easiest way to calculate shareholders equity is to subtract the companys total liabilities from the total assets.

Return on Equity measures a companys profitability against the profit it has kept for the business (plus any capital injections). The return is the profit over the last twelve months. A higher profit will lead to a higher ROE. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. However, this method is only useful as a rough check, because companies do differ quite a bit within the same industry classification. As is clear from the image below, Avecho Biotechnology has a lower ROE than the average (7.7%) in the Pharmaceuticals industry.

That certainly isnt ideal. Wed prefer see an ROE above the industry average, but it might not matter if the company is undervalued. Nonetheless, it might be wise to check if insiders have been selling.

Most companies need money from somewhere to grow their profits. That cash can come from retained earnings, issuing new shares (equity), or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Avecho Biotechnology is free of net debt, which is a positive for shareholders. Without a doubt it has a fairly low ROE, but that isnt so bad when you consider it has no debt. At the end of the day, when a company has zero debt, it is in a better position to take future growth opportunities.

Return on equity is useful for comparing the quality of different businesses. A company that can achieve a high return on equity without debt could be considered a high quality business. If two companies have the same ROE, then I would generally prefer the one with less debt.

But when a business is high quality, the market often bids it up to a price that reflects this. It is important to consider other factors, such as future profit growth and how much investment is required going forward. Check the past profit growth by Avecho Biotechnology by looking at this visualization of past earnings, revenue and cash flow.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Read this article:
Read This Before Judging Avecho Biotechnology Limiteds (ASX:AVE) ROE - Simply Wall St

Read More...

Here’s Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today – Motley Fool

February 8th, 2020 3:47 am

What happened

Shares of Inovio Pharmaceuticals (NASDAQ:INO) and Vir Biotechnology (NASDAQ:VIR), two companies developing drugs for the coronavirus outbreak in China, are down today on word that Gilead Sciences (NASDAQ:GILD) looks to have beaten the companies to the punch, setting up a research collaboration with Chinese authorities to run a clinical trial for its antiviral medication remdesivir.

As of 1:46 p.m. EST on Monday, Inovio had fallen 14.5%, while Vir was down 16.2%.

Image source: Getty Images.

While the news that Gilead has moved first is disappointing for the biotechs, there may still be a need for Inovio's 2019-nCoV coronavirus vaccine. Remdesivir might lessen the symptoms of the virus, but it won't stop the spread of the disease in mildly symptomatic patients who aren't likely to take the drug.

Vir's antibody treatment would likely compete more directly with remdesivir since it would attack the virus directly and would likely be used to treat infected patients.

Both Inovio and Vir increased in value quite a bit in January. Vir doubled, while Inovio was up almost 40% as the 2019-nCoV coronavirus outbreak has spread and investors pinned hopes on the potential to develop drugs for the virus. With the valuations already incorporating some of the potential, it's not surprising to see a pullback on news that the opportunity might not be as large as first imagined.

The bigger issue for Inovio and Vir is how long the clinical trial process could end up taking and whether the outbreak will peter out before the companies can get their treatments to market.

Continue reading here:
Here's Why Inovio Pharmaceuticals and Vir Biotechnology Shares Have Fallen Today - Motley Fool

Read More...

Page 723«..1020..722723724725..730740..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick